Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | TDO2 | P48775 | 2/20 | 0.58 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.58 |
| ▸ | HPD | P32754 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6602737 | 0.88 | L3MBTL1 (0.74) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL6601051 | 0.87 | ALDH1A1 (0.70) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL6214049 | 0.85 | L3MBTL1 (0.62) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL30726101 | 0.84 | ALDH1A1 (0.73) | L3MBTL1GLAHPDPOLBHCAR1 | |
| SCHEMBL1551591 | 0.84 | ALDH1A1 (0.73) | L3MBTL1GLAHPDPOLBHCAR1 | |
| SCHEMBL22238067 | 0.82 | POLB (0.72) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL6215809 | 0.81 | L3MBTL1 (0.57) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL31196727 | 0.80 | POLB (0.61) | L3MBTL1GLATDO2IDO2HPD | |
| SCHEMBL6220136 | 0.79 | L3MBTL1 (0.55) | L3MBTL1GLATDO2IDO2POLB | |
| SCHEMBL18332822 | 0.77 | POLB (0.65) | L3MBTL1GLATDO2IDO2HPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901487-B9 | 2,3,6 TRISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-0968194-B1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-0901487-B1 | 2,3,6 TRISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| CN-1420114-A | 2,3-disubstd. -4(3H)-quinazolones | PFIZER (US) | 2003-05-28 | — | — | CN | disclosed |
| CN-1103772-C | Novel 2, 3-disubstituted-4 (3H) -quinazolinones | PFIZER (US) | 2003-03-26 | — | — | CN | disclosed |
| US-6306864-B1 | CEREBRAL DEFICITS SUBSEQUENT TO OR RESULTING FROM CARDIAC BYPASS SURGERY AND GRAFTING, STROKE, CEREBRAL ISCHEMIA, SPINAL CORD TRAUMA, HEAD TRAUMA | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303615-B1 | FOR THERAPY AND PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, CONVULSIONS | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| CN-1248248-A | Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists | PFIZER PROD INC (US) | 2000-03-22 | — | — | CN | disclosed |
| EP-0968194-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| CN-1218464-A | Novel 2, 3-disubstituted-4 (3H) -quinazolinones | PFIZER (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0901487-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998038173-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1997043276-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |